Hans-Joachim Anders
@hjanders.bsky.social
Physician scientist from LMU Munich trying to understand how to maximise kidney lifespan for patients with kidney diseases
Now open access in @ndt-era.bsky.social
Rationale, Design, and Baseline Characteristics of the TRANSCEND-CKD trial of Retatrutide in pts with CKD
🧐Retatrutide is a novel triple incretin agonist targeting GIP, GLP-1, and glucagon receptors
▶️ academic.oup.com/ndt/article/...
Rationale, Design, and Baseline Characteristics of the TRANSCEND-CKD trial of Retatrutide in pts with CKD
🧐Retatrutide is a novel triple incretin agonist targeting GIP, GLP-1, and glucagon receptors
▶️ academic.oup.com/ndt/article/...
October 30, 2025 at 8:56 AM
Now open access in @ndt-era.bsky.social
Rationale, Design, and Baseline Characteristics of the TRANSCEND-CKD trial of Retatrutide in pts with CKD
🧐Retatrutide is a novel triple incretin agonist targeting GIP, GLP-1, and glucagon receptors
▶️ academic.oup.com/ndt/article/...
Rationale, Design, and Baseline Characteristics of the TRANSCEND-CKD trial of Retatrutide in pts with CKD
🧐Retatrutide is a novel triple incretin agonist targeting GIP, GLP-1, and glucagon receptors
▶️ academic.oup.com/ndt/article/...
Now open access in @ndt-era.bsky.social
Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD) in Chinese Pts
🧐This Chinese ADTKD cohort reveals a high prevalence of UMOD and HNF1B variants
▶️ academic.oup.com/ndt/article-...
Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD) in Chinese Pts
🧐This Chinese ADTKD cohort reveals a high prevalence of UMOD and HNF1B variants
▶️ academic.oup.com/ndt/article-...
October 28, 2025 at 9:45 AM
Now open access in @ndt-era.bsky.social
Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD) in Chinese Pts
🧐This Chinese ADTKD cohort reveals a high prevalence of UMOD and HNF1B variants
▶️ academic.oup.com/ndt/article-...
Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD) in Chinese Pts
🧐This Chinese ADTKD cohort reveals a high prevalence of UMOD and HNF1B variants
▶️ academic.oup.com/ndt/article-...
Now online in @ndt-era.bsky.social
Neutrophil infiltration of kidney grafts: incidence, associated factors and graft survival
🧐NTI should prompt the search for urinary tract infection and rejection
▶️ academic.oup.com/ndt/article-...
Neutrophil infiltration of kidney grafts: incidence, associated factors and graft survival
🧐NTI should prompt the search for urinary tract infection and rejection
▶️ academic.oup.com/ndt/article-...
October 28, 2025 at 9:41 AM
Now online in @ndt-era.bsky.social
Neutrophil infiltration of kidney grafts: incidence, associated factors and graft survival
🧐NTI should prompt the search for urinary tract infection and rejection
▶️ academic.oup.com/ndt/article-...
Neutrophil infiltration of kidney grafts: incidence, associated factors and graft survival
🧐NTI should prompt the search for urinary tract infection and rejection
▶️ academic.oup.com/ndt/article-...
Now open access in @ndt-era.bsky.social
How can we target the production of pathogenic IgA in IgAN?
🧐Drugs directed at mucosal B cells, inhibitors of APRIL and BAFF, and drugs that target IgA-producing plasma cells
▶️https://academic.oup.com/ndt/article/doi/10.1093/ndt/gfaf185/8262262
How can we target the production of pathogenic IgA in IgAN?
🧐Drugs directed at mucosal B cells, inhibitors of APRIL and BAFF, and drugs that target IgA-producing plasma cells
▶️https://academic.oup.com/ndt/article/doi/10.1093/ndt/gfaf185/8262262
October 8, 2025 at 9:56 AM
Now open access in @ndt-era.bsky.social
How can we target the production of pathogenic IgA in IgAN?
🧐Drugs directed at mucosal B cells, inhibitors of APRIL and BAFF, and drugs that target IgA-producing plasma cells
▶️https://academic.oup.com/ndt/article/doi/10.1093/ndt/gfaf185/8262262
How can we target the production of pathogenic IgA in IgAN?
🧐Drugs directed at mucosal B cells, inhibitors of APRIL and BAFF, and drugs that target IgA-producing plasma cells
▶️https://academic.oup.com/ndt/article/doi/10.1093/ndt/gfaf185/8262262
Now online in @ndt-era.bsky.social
Recombinant alpha-1 microglobulin to improve outcomes in survivors of AKI
🧐RMC-035 may improve kidney outcomes in settings characterized by oxidative and ischemia-reperfusion injury.
▶️ academic.oup.com/ndt/article-...
Recombinant alpha-1 microglobulin to improve outcomes in survivors of AKI
🧐RMC-035 may improve kidney outcomes in settings characterized by oxidative and ischemia-reperfusion injury.
▶️ academic.oup.com/ndt/article-...
September 30, 2025 at 2:09 PM
Now online in @ndt-era.bsky.social
Recombinant alpha-1 microglobulin to improve outcomes in survivors of AKI
🧐RMC-035 may improve kidney outcomes in settings characterized by oxidative and ischemia-reperfusion injury.
▶️ academic.oup.com/ndt/article-...
Recombinant alpha-1 microglobulin to improve outcomes in survivors of AKI
🧐RMC-035 may improve kidney outcomes in settings characterized by oxidative and ischemia-reperfusion injury.
▶️ academic.oup.com/ndt/article-...
Now open access in @ndt-era.bsky.social
Prevalence of Strongyloides stercoralis in HD pts in Vienna
🧐Implementation of targeted screening for S. stercoralis should be considered in pre-KTX protocols in Europe.
▶️ academic.oup.com/ndt/article/...
Prevalence of Strongyloides stercoralis in HD pts in Vienna
🧐Implementation of targeted screening for S. stercoralis should be considered in pre-KTX protocols in Europe.
▶️ academic.oup.com/ndt/article/...
September 28, 2025 at 8:52 AM
Now open access in @ndt-era.bsky.social
Prevalence of Strongyloides stercoralis in HD pts in Vienna
🧐Implementation of targeted screening for S. stercoralis should be considered in pre-KTX protocols in Europe.
▶️ academic.oup.com/ndt/article/...
Prevalence of Strongyloides stercoralis in HD pts in Vienna
🧐Implementation of targeted screening for S. stercoralis should be considered in pre-KTX protocols in Europe.
▶️ academic.oup.com/ndt/article/...
Now open access in @ndt-era.bsky.social
QT-Prolonging Medications: Prevalence of Use and Associated Risks in CKD
🧐The pathophysiological relevance, prevalence, and CV consequences of QT-prolonging drug use in the CKD setting
▶️https://academic.oup.com/ndt/article/doi/10.1093/ndt/gfaf196/8263915
QT-Prolonging Medications: Prevalence of Use and Associated Risks in CKD
🧐The pathophysiological relevance, prevalence, and CV consequences of QT-prolonging drug use in the CKD setting
▶️https://academic.oup.com/ndt/article/doi/10.1093/ndt/gfaf196/8263915
September 27, 2025 at 9:14 PM
Now open access in @ndt-era.bsky.social
QT-Prolonging Medications: Prevalence of Use and Associated Risks in CKD
🧐The pathophysiological relevance, prevalence, and CV consequences of QT-prolonging drug use in the CKD setting
▶️https://academic.oup.com/ndt/article/doi/10.1093/ndt/gfaf196/8263915
QT-Prolonging Medications: Prevalence of Use and Associated Risks in CKD
🧐The pathophysiological relevance, prevalence, and CV consequences of QT-prolonging drug use in the CKD setting
▶️https://academic.oup.com/ndt/article/doi/10.1093/ndt/gfaf196/8263915
Now open access in @NDTsocial
Anti-GBM disease - Treatment Standard
🧐 Anti-GBM and ANCA positive pts have a higher relapse risk and require maintenance immunosuppressive treatment
▶️ academic.oup.com/ndt/article/...
Anti-GBM disease - Treatment Standard
🧐 Anti-GBM and ANCA positive pts have a higher relapse risk and require maintenance immunosuppressive treatment
▶️ academic.oup.com/ndt/article/...
September 18, 2025 at 8:15 PM
Now open access in @NDTsocial
Anti-GBM disease - Treatment Standard
🧐 Anti-GBM and ANCA positive pts have a higher relapse risk and require maintenance immunosuppressive treatment
▶️ academic.oup.com/ndt/article/...
Anti-GBM disease - Treatment Standard
🧐 Anti-GBM and ANCA positive pts have a higher relapse risk and require maintenance immunosuppressive treatment
▶️ academic.oup.com/ndt/article/...
Now open access in @ndt-era.bsky.social
Comparing CKD populations with T1D and T2D based on FINE-ONE and FIDELITY populations
🧐Similarities between populations may inform the translation of clinical evidence on finerenone from CKD and T2D to CKD and T1D.
▶️ academic.oup.com/ndt/article/...
Comparing CKD populations with T1D and T2D based on FINE-ONE and FIDELITY populations
🧐Similarities between populations may inform the translation of clinical evidence on finerenone from CKD and T2D to CKD and T1D.
▶️ academic.oup.com/ndt/article/...
September 16, 2025 at 10:55 AM
Now open access in @ndt-era.bsky.social
Comparing CKD populations with T1D and T2D based on FINE-ONE and FIDELITY populations
🧐Similarities between populations may inform the translation of clinical evidence on finerenone from CKD and T2D to CKD and T1D.
▶️ academic.oup.com/ndt/article/...
Comparing CKD populations with T1D and T2D based on FINE-ONE and FIDELITY populations
🧐Similarities between populations may inform the translation of clinical evidence on finerenone from CKD and T2D to CKD and T1D.
▶️ academic.oup.com/ndt/article/...
Now open access in @ndt-era.bsky.social al
CKD of unexplained cause (CKDx): A consensus statement by the Genes &Kidney Working Group of the ERA
🧐Check also our 2 open access editorials on this innovative concept.
▶️ academic.oup.com/ndt/article/...
CKD of unexplained cause (CKDx): A consensus statement by the Genes &Kidney Working Group of the ERA
🧐Check also our 2 open access editorials on this innovative concept.
▶️ academic.oup.com/ndt/article/...
September 14, 2025 at 8:28 AM
Now open access in @ndt-era.bsky.social al
CKD of unexplained cause (CKDx): A consensus statement by the Genes &Kidney Working Group of the ERA
🧐Check also our 2 open access editorials on this innovative concept.
▶️ academic.oup.com/ndt/article/...
CKD of unexplained cause (CKDx): A consensus statement by the Genes &Kidney Working Group of the ERA
🧐Check also our 2 open access editorials on this innovative concept.
▶️ academic.oup.com/ndt/article/...
Now online in @ndt-era.bsky.social
Transition of pts with hereditary nephropathies from pediatric to adult care
from WG Genes&Kidney of ERA and ESPN
🧐To improve health outcomes, pt empowerment, and engagement for young people with CKD.
▶️ academic.oup.com/ndt/article-...
Transition of pts with hereditary nephropathies from pediatric to adult care
from WG Genes&Kidney of ERA and ESPN
🧐To improve health outcomes, pt empowerment, and engagement for young people with CKD.
▶️ academic.oup.com/ndt/article-...
September 12, 2025 at 7:42 AM
Now online in @ndt-era.bsky.social
Transition of pts with hereditary nephropathies from pediatric to adult care
from WG Genes&Kidney of ERA and ESPN
🧐To improve health outcomes, pt empowerment, and engagement for young people with CKD.
▶️ academic.oup.com/ndt/article-...
Transition of pts with hereditary nephropathies from pediatric to adult care
from WG Genes&Kidney of ERA and ESPN
🧐To improve health outcomes, pt empowerment, and engagement for young people with CKD.
▶️ academic.oup.com/ndt/article-...
New RCT online in @ndt-era.bsky.social
Additive Effects of Oral Calcitriol on pts with IgAN receiving RAS Blockade
🧐The addition of 0.25 μg/d calcitriol to RASi safely lowered residual proteinuria and slowed eGFR decline in pts with IgAN
▶️ academic.oup.com/ndt/article-...
Additive Effects of Oral Calcitriol on pts with IgAN receiving RAS Blockade
🧐The addition of 0.25 μg/d calcitriol to RASi safely lowered residual proteinuria and slowed eGFR decline in pts with IgAN
▶️ academic.oup.com/ndt/article-...
September 12, 2025 at 7:29 AM
New RCT online in @ndt-era.bsky.social
Additive Effects of Oral Calcitriol on pts with IgAN receiving RAS Blockade
🧐The addition of 0.25 μg/d calcitriol to RASi safely lowered residual proteinuria and slowed eGFR decline in pts with IgAN
▶️ academic.oup.com/ndt/article-...
Additive Effects of Oral Calcitriol on pts with IgAN receiving RAS Blockade
🧐The addition of 0.25 μg/d calcitriol to RASi safely lowered residual proteinuria and slowed eGFR decline in pts with IgAN
▶️ academic.oup.com/ndt/article-...
Now open access in @ndt-era.bsky.social
Protein profiles and associated biological pathways among different etiologies of CKD: new insights from DAPA-CKD
🧐Distinct proteomic differences unravel the heterogeneous pathophysiology of human CKD.
▶️ academic.oup.com/ndt/article/...
Protein profiles and associated biological pathways among different etiologies of CKD: new insights from DAPA-CKD
🧐Distinct proteomic differences unravel the heterogeneous pathophysiology of human CKD.
▶️ academic.oup.com/ndt/article/...
September 8, 2025 at 7:42 PM
Now open access in @ndt-era.bsky.social
Protein profiles and associated biological pathways among different etiologies of CKD: new insights from DAPA-CKD
🧐Distinct proteomic differences unravel the heterogeneous pathophysiology of human CKD.
▶️ academic.oup.com/ndt/article/...
Protein profiles and associated biological pathways among different etiologies of CKD: new insights from DAPA-CKD
🧐Distinct proteomic differences unravel the heterogeneous pathophysiology of human CKD.
▶️ academic.oup.com/ndt/article/...
Now open access in @ndt-era.bsky.social
Anti-nephrin, anti-podocin and anti-Kirrel1 antibodies: Biological challenges and clinical implications
🧐 Clinical implementation of anti-slit diaphragm antibody testing = precision dx and tx in podocytopathies
▶️ academic.oup.com/ndt/article/...
Anti-nephrin, anti-podocin and anti-Kirrel1 antibodies: Biological challenges and clinical implications
🧐 Clinical implementation of anti-slit diaphragm antibody testing = precision dx and tx in podocytopathies
▶️ academic.oup.com/ndt/article/...
August 16, 2025 at 6:59 AM
Now open access in @ndt-era.bsky.social
Anti-nephrin, anti-podocin and anti-Kirrel1 antibodies: Biological challenges and clinical implications
🧐 Clinical implementation of anti-slit diaphragm antibody testing = precision dx and tx in podocytopathies
▶️ academic.oup.com/ndt/article/...
Anti-nephrin, anti-podocin and anti-Kirrel1 antibodies: Biological challenges and clinical implications
🧐 Clinical implementation of anti-slit diaphragm antibody testing = precision dx and tx in podocytopathies
▶️ academic.oup.com/ndt/article/...
Now open access in @ndt-era.bsky.social
What do RCTs teach us about the pathophysiology of human IgAN?
🧐B cells/PC produce the IgAN antigen GdIgA1 as well as the respective autoantibodies, hence targeting B cells/PC will be most clever.
▶️ academic.oup.com/ndt/article/...
What do RCTs teach us about the pathophysiology of human IgAN?
🧐B cells/PC produce the IgAN antigen GdIgA1 as well as the respective autoantibodies, hence targeting B cells/PC will be most clever.
▶️ academic.oup.com/ndt/article/...
August 13, 2025 at 8:16 AM
Now open access in @ndt-era.bsky.social
What do RCTs teach us about the pathophysiology of human IgAN?
🧐B cells/PC produce the IgAN antigen GdIgA1 as well as the respective autoantibodies, hence targeting B cells/PC will be most clever.
▶️ academic.oup.com/ndt/article/...
What do RCTs teach us about the pathophysiology of human IgAN?
🧐B cells/PC produce the IgAN antigen GdIgA1 as well as the respective autoantibodies, hence targeting B cells/PC will be most clever.
▶️ academic.oup.com/ndt/article/...
Now online in @ndt-era.bsky.social
Perlecan is a novel target of autoantibodies in anti-glomerular basement membrane disease
🧐Triple-positive pts (anti-type IV collagen, -laminin 521, and -perlecan) = highest prevalence of lung hemorrhage and ESKD
▶️ academic.oup.com/ndt/article-...
Perlecan is a novel target of autoantibodies in anti-glomerular basement membrane disease
🧐Triple-positive pts (anti-type IV collagen, -laminin 521, and -perlecan) = highest prevalence of lung hemorrhage and ESKD
▶️ academic.oup.com/ndt/article-...
August 12, 2025 at 5:27 AM
Now online in @ndt-era.bsky.social
Perlecan is a novel target of autoantibodies in anti-glomerular basement membrane disease
🧐Triple-positive pts (anti-type IV collagen, -laminin 521, and -perlecan) = highest prevalence of lung hemorrhage and ESKD
▶️ academic.oup.com/ndt/article-...
Perlecan is a novel target of autoantibodies in anti-glomerular basement membrane disease
🧐Triple-positive pts (anti-type IV collagen, -laminin 521, and -perlecan) = highest prevalence of lung hemorrhage and ESKD
▶️ academic.oup.com/ndt/article-...
Now open access in @ndt-era.bsky.social
Evolving strategies for early diagnosis, proactive prevention and treatment of CKD
🧐"Inferior doctors provide KRT
Mediocre doctors treat CKD
Superior doctors prevent kidney disease"
▶️
academic.oup.com/ndt/article/...
Evolving strategies for early diagnosis, proactive prevention and treatment of CKD
🧐"Inferior doctors provide KRT
Mediocre doctors treat CKD
Superior doctors prevent kidney disease"
▶️
academic.oup.com/ndt/article/...
August 11, 2025 at 9:08 AM
Now open access in @ndt-era.bsky.social
Evolving strategies for early diagnosis, proactive prevention and treatment of CKD
🧐"Inferior doctors provide KRT
Mediocre doctors treat CKD
Superior doctors prevent kidney disease"
▶️
academic.oup.com/ndt/article/...
Evolving strategies for early diagnosis, proactive prevention and treatment of CKD
🧐"Inferior doctors provide KRT
Mediocre doctors treat CKD
Superior doctors prevent kidney disease"
▶️
academic.oup.com/ndt/article/...
Now online in @ndt-era.bsky.social
Acute post-streptococcal GN (in children) - treatment standard
🧐 Pathophysiology, diagnosis, outcome prediction, and management standard
▶️ academic.oup.com/ndt/article-...
Acute post-streptococcal GN (in children) - treatment standard
🧐 Pathophysiology, diagnosis, outcome prediction, and management standard
▶️ academic.oup.com/ndt/article-...
July 13, 2025 at 8:24 AM
Now online in @ndt-era.bsky.social
Acute post-streptococcal GN (in children) - treatment standard
🧐 Pathophysiology, diagnosis, outcome prediction, and management standard
▶️ academic.oup.com/ndt/article-...
Acute post-streptococcal GN (in children) - treatment standard
🧐 Pathophysiology, diagnosis, outcome prediction, and management standard
▶️ academic.oup.com/ndt/article-...
Now online in @ndt-era.bsky.social
Multifactorial chronic kidney disease
🧐 Life is long and our kidneys have to take many hits, hence, adult CKD is usually multifactorial as is atherosclerosis or dementia. RF control is key and RF vary across world regions
▶️ academic.oup.com/ndt/article-...
Multifactorial chronic kidney disease
🧐 Life is long and our kidneys have to take many hits, hence, adult CKD is usually multifactorial as is atherosclerosis or dementia. RF control is key and RF vary across world regions
▶️ academic.oup.com/ndt/article-...
July 12, 2025 at 7:27 AM
Now online in @ndt-era.bsky.social
Multifactorial chronic kidney disease
🧐 Life is long and our kidneys have to take many hits, hence, adult CKD is usually multifactorial as is atherosclerosis or dementia. RF control is key and RF vary across world regions
▶️ academic.oup.com/ndt/article-...
Multifactorial chronic kidney disease
🧐 Life is long and our kidneys have to take many hits, hence, adult CKD is usually multifactorial as is atherosclerosis or dementia. RF control is key and RF vary across world regions
▶️ academic.oup.com/ndt/article-...
Now online in @ndt-era.bsky.social
Treatment standard: CKD in the geriatric patient
🧐Pat.-centered communication about preferences and prioritized Tx goals sonsiders psychosocial factors and home environment, as well as their medical needs and prognosis
▶️ academic.oup.com/ndt/article-...
Treatment standard: CKD in the geriatric patient
🧐Pat.-centered communication about preferences and prioritized Tx goals sonsiders psychosocial factors and home environment, as well as their medical needs and prognosis
▶️ academic.oup.com/ndt/article-...
July 12, 2025 at 7:07 AM
Now online in @ndt-era.bsky.social
Treatment standard: CKD in the geriatric patient
🧐Pat.-centered communication about preferences and prioritized Tx goals sonsiders psychosocial factors and home environment, as well as their medical needs and prognosis
▶️ academic.oup.com/ndt/article-...
Treatment standard: CKD in the geriatric patient
🧐Pat.-centered communication about preferences and prioritized Tx goals sonsiders psychosocial factors and home environment, as well as their medical needs and prognosis
▶️ academic.oup.com/ndt/article-...
The new Impact factors are out. Here is a list of some kidney journals @ndt-era.bsky.social
June 18, 2025 at 9:45 AM
The new Impact factors are out. Here is a list of some kidney journals @ndt-era.bsky.social
Ongoing discussion about UACR or UPCR in GN captured in @ndt-era.bsky.social
The use of UACR or UPCR for risk prediction in IgAN
url:https://academic.oup.com/ndt/article-abstract/40/1/1/7702452
UACR predicts kidney events in IgAN
url:https://academic.oup.com/ndt/article/40/3/465/7660570
The use of UACR or UPCR for risk prediction in IgAN
url:https://academic.oup.com/ndt/article-abstract/40/1/1/7702452
UACR predicts kidney events in IgAN
url:https://academic.oup.com/ndt/article/40/3/465/7660570
June 17, 2025 at 10:55 AM
Ongoing discussion about UACR or UPCR in GN captured in @ndt-era.bsky.social
The use of UACR or UPCR for risk prediction in IgAN
url:https://academic.oup.com/ndt/article-abstract/40/1/1/7702452
UACR predicts kidney events in IgAN
url:https://academic.oup.com/ndt/article/40/3/465/7660570
The use of UACR or UPCR for risk prediction in IgAN
url:https://academic.oup.com/ndt/article-abstract/40/1/1/7702452
UACR predicts kidney events in IgAN
url:https://academic.oup.com/ndt/article/40/3/465/7660570
Now open access in @ndt-era.bsky.social
Antibody-mediated Rejection - Treatment Standard
🧐Ongoing phase 2 trials offer hope for effective, therapies targeting different aspects of AMR.
academic.oup.com/ndt/article/...
Antibody-mediated Rejection - Treatment Standard
🧐Ongoing phase 2 trials offer hope for effective, therapies targeting different aspects of AMR.
academic.oup.com/ndt/article/...
June 3, 2025 at 6:11 AM
Now open access in @ndt-era.bsky.social
Antibody-mediated Rejection - Treatment Standard
🧐Ongoing phase 2 trials offer hope for effective, therapies targeting different aspects of AMR.
academic.oup.com/ndt/article/...
Antibody-mediated Rejection - Treatment Standard
🧐Ongoing phase 2 trials offer hope for effective, therapies targeting different aspects of AMR.
academic.oup.com/ndt/article/...
Now open access in the June edition of @ndt-era.bsky.social
Disease-modifying anti-nephropathic drugs (DMANDs)—a definition proposed by the IWG of ERA
🧐Not all drugs that reduce UPCR may be disease-modifying. SGLT2i are a DMAND only for GN-related CKD.
academic.oup.com/ndt/article/...
Disease-modifying anti-nephropathic drugs (DMANDs)—a definition proposed by the IWG of ERA
🧐Not all drugs that reduce UPCR may be disease-modifying. SGLT2i are a DMAND only for GN-related CKD.
academic.oup.com/ndt/article/...
June 2, 2025 at 6:12 AM
Now open access in the June edition of @ndt-era.bsky.social
Disease-modifying anti-nephropathic drugs (DMANDs)—a definition proposed by the IWG of ERA
🧐Not all drugs that reduce UPCR may be disease-modifying. SGLT2i are a DMAND only for GN-related CKD.
academic.oup.com/ndt/article/...
Disease-modifying anti-nephropathic drugs (DMANDs)—a definition proposed by the IWG of ERA
🧐Not all drugs that reduce UPCR may be disease-modifying. SGLT2i are a DMAND only for GN-related CKD.
academic.oup.com/ndt/article/...